The viral load monitoring cascade in HIV treatment programmes in sub-Saharan Africa: a systematic review
The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Sahar...
Saved in:
| Published in | BMC public health Vol. 24; no. 1; pp. 2603 - 17 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
27.09.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets.
A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression].
The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression.
VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. |
|---|---|
| AbstractList | The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets.BACKGROUNDThe United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets.A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression].METHODSA literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression].The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression.RESULTSThe initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression.VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030.CONCLUSIONSVL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets. A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression]. The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression. VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets. A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression]. The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression. VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. Background The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets. Methods A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression]. Results The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression. Conclusions VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. Keywords: HIV, Viral load monitoring, Sub-Saharan Africa, Failure cascade, Decentralisation BackgroundThe United Nations’ 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets.MethodsA literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression].ResultsThe initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression.ConclusionsVL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. Abstract Background The United Nations’ 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression) target aims to reduce morbidity and mortality of HIV. However, with 60% of new HIV infections occurring in sub-Saharan Africa (SSA), achieving this target in the region is challenging. Viral load (VL) monitoring is the gold-standard approach of assessing treatment efficacy, and its implementation into national health systems is a global health priority if elimination of HIV as a public health threat is to be achieved by 2030. This systematic review aims to investigate VL monitoring outcomes in SSA, and to identify gaps and possible interventions to help nations meet their 2030 targets. Methods A literature search of three electronic platforms (MEDLINE, EMBASE and Global Health) was undertaken from 1 January to 9 August 2024 to identify studies published in English and conducted in SSA. The primary outcome was the proportion of people living with HIV (PLHIV) on antiretroviral therapy (ART) with routine VL monitoring at the recommended time points (initially, 6 months, 12 months and annually). Secondary outcomes reported proportions of PLHIV who received routine VL monitoring who went on to complete the cascade of care after identified virological failure [enhanced adherence counselling (EAC), switch to second-line ART, and finally viral suppression]. Results The initial search identified 342 papers, of which 35 studies were included for narrative synthesis. Included studies reported on findings from 14 African countries and demonstrated extensive variation in rates of VL monitoring (range: 24.3-99.7%, mean: 63.8%). Results were more unfavourable in the latter steps of the viral load monitoring cascade, with a range of 0-88%, and a switch to second-line ART mean of 42% (range: 4.4-93%). Studies with additional support, and those with community-based models of care, had higher rates of VL testing and viral suppression. Conclusions VL monitoring and management of virological failure are suboptimal in many SSA countries due to individual and health system-related challenges. Health system strengthening is vital to ensure the sustainability of HIV treatment programmes and the achievement of 95-95-95 targets by 2030. |
| ArticleNumber | 2603 |
| Audience | Academic |
| Author | Iwuji, Collins Nzimande, Londiwe Kippen, Annalise Gareta, Dickman |
| Author_xml | – sequence: 1 givenname: Annalise surname: Kippen fullname: Kippen, Annalise organization: Brighton and Sussex Medical School, Brighton, UK – sequence: 2 givenname: Londiwe surname: Nzimande fullname: Nzimande, Londiwe organization: Africa Health Research Institute, KwaZulu-Natal, South Africa – sequence: 3 givenname: Dickman surname: Gareta fullname: Gareta, Dickman organization: Africa Health Research Institute, KwaZulu-Natal, South Africa – sequence: 4 givenname: Collins surname: Iwuji fullname: Iwuji, Collins email: c.iwuji@bsms.ac.uk, c.iwuji@bsms.ac.uk organization: Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, UK. c.iwuji@bsms.ac.uk |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39334013$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkktv1DAUhSNURB_wB1ggS2zYpPiVjM1uVEE7UiUWFLbWjXM941FiFzvTx7_H6bRVQaxs2d85vkc-x9VBiAGr6j2jp4yp9nNmXCldUy5rTikT9d2r6ojJBau5bNTBi_1hdZzztjAL1fA31aHQQsiiOKo2VxskNz7BQIYIPRlj8FNMPqyJhWyhR-IDuVj9IlNCmEYME7lOcZ1gHDHPd3nX1T9gAwkCWbrkLXwhQPJ9nnCEyVuS8Mbj7dvqtYMh47vH9aT6-e3r1dlFffn9fHW2vKytUHqqRSekbKkDp4W2yNEBSKXtAtE651rKuJXImOg1NNJS6VBZqmTbWWqLWJxUq71vH2FrrpMfId2bCN48HMS0NpDKWAMa1E2nXTHsu0ZSKbVsmGQMGJOUQq-K16e9V0n8e4d5MqPPFocBAsZdNoIxqmnbKl3Qj_-g27hLoSSdqYbxheYvqDWU931wcUpgZ1OzVIxKWsLTQp3-h4L5M0ZvSwecL-d_CfheYFPMOaF7zs2omati9lUxpSrmoSrmrog-PE6860bsnyVP3RB_APZ0uRE |
| Cites_doi | 10.1136/bmj.n71 10.1371/journal.pone.0198686 10.7448/IAS.20.1.21803 10.1128/CMR.00097-18 10.1016/S2352-3018(20)30188-0 10.1186/s12889-022-13504-2 10.5588/pha.18.0063 10.1002/jia2.25476 10.1371/journal.pone.0124748 10.1371/journal.pone.0253164 10.1371/journal.pone.0304487 10.7196/SAMJ.2021.v111i4.15432 10.15585/mmwr.mm7021a2 10.1371/journal.pone.0220337 10.1186/s12981-017-0131-5 10.1002/jia2.25543 10.1089/aid.2020.0049 10.1186/s12879-020-05461-1 10.5588/pha.19.0067 10.1371/journal.pone.0223573 10.1371/journal.pone.0225476 10.1016/j.socscimed.2016.09.027 10.1186/s12976-017-0062-9 10.7196/SAMJ.2019.v109i3.13456 10.1111/hiv.12877 10.1093/trstmh/trt071 10.11604/pamj.2020.36.37.19046 10.1002/jia2.26005 10.4102/sajhivmed.v21i1.1085 10.1371/journal.pmed.1003037 10.1371/journal.pone.0266159 10.1002/jia2.25387 10.1016/S2352-3018(23)00118-2 10.1097/QAD.0000000000001964 10.1093/inthealth/ihx021 10.1136/sextrans-2018-053854 10.1371/journal.pone.0245720 10.1186/s12879-018-3639-y 10.1002/jia2.25194 10.1371/journal.pone.0239087 10.1186/s12879-022-07692-w 10.1111/hiv.13126 10.1093/cid/ciac605 10.1097/QAD.0b013e328349822f 10.5588/pha.19.0024 10.7448/IAS.20.5.21649 10.1371/journal.pone.0218649 10.3402/gha.v9.29943 10.1089/apc.2019.0055 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T2 7X7 7XB 88E 8C1 8FE 8FG 8FI 8FJ 8FK ABJCF ABUWG AFKRA AN0 ATCPS AZQEC BENPR BGLVJ BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V M0S M1P M7S PATMY PIMPY PQEST PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 DOA |
| DOI | 10.1186/s12889-024-20013-x |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central British Nursing Database Agricultural & Environmental Science Collection ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Engineering Database Environmental Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection MEDLINE - Academic Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Agricultural & Environmental Science Collection Health & Safety Science Abstracts ProQuest Medical Library (Alumni) Engineering Collection Engineering Database ProQuest Public Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 1471-2458 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_e95b9f12cdb540449451411a11400ad8 A810403440 10_1186_s12889_024_20013_x 39334013 |
| Genre | Systematic Review Journal Article |
| GeographicLocations | Africa South of the Sahara Sub-Saharan Africa Africa |
| GeographicLocations_xml | – name: Africa South of the Sahara – name: Sub-Saharan Africa – name: Africa |
| GrantInformation_xml | – fundername: Royal Academy of Engineering grantid: FF\1920\1\23 |
| GroupedDBID | --- -A0 0R~ 23N 2WC 2XV 3V. 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACRMQ ADBBV ADINQ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR ITC KQ8 L6V M1P M7S M~E NPM O5R O5S OK1 P2P PATMY PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION 7T2 7XB 8FK AZQEC C1K DWQXO GNUQQ K9. M48 PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c389t-3b34460faf939ce2efaa489c7eecfff6012c4e113d9a54c04fe8c0846bc0c3b33 |
| IEDL.DBID | 8FG |
| ISSN | 1471-2458 |
| IngestDate | Tue Oct 22 15:14:44 EDT 2024 Sat Oct 26 02:11:32 EDT 2024 Mon Nov 25 20:06:58 EST 2024 Tue Nov 19 21:29:47 EST 2024 Tue Oct 08 04:18:43 EDT 2024 Fri Nov 22 01:51:20 EST 2024 Sat Nov 02 12:02:12 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Decentralisation Viral load monitoring HIV Sub-Saharan Africa Failure cascade |
| Language | English |
| License | 2024. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c389t-3b34460faf939ce2efaa489c7eecfff6012c4e113d9a54c04fe8c0846bc0c3b33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/docview/3115127929?pq-origsite=%requestingapplication% |
| PMID | 39334013 |
| PQID | 3115127929 |
| PQPubID | 44782 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e95b9f12cdb540449451411a11400ad8 proquest_miscellaneous_3110906689 proquest_journals_3115127929 gale_infotracmisc_A810403440 gale_infotracacademiconefile_A810403440 crossref_primary_10_1186_s12889_024_20013_x pubmed_primary_39334013 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-27 |
| PublicationDateYYYYMMDD | 2024-09-27 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-27 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC public health |
| PublicationTitleAlternate | BMC Public Health |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 20013_CR53 20013_CR10 20013_CR54 20013_CR55 M Remme (20013_CR82) 2016; 169 20013_CR12 20013_CR56 20013_CR13 20013_CR57 20013_CR58 20013_CR59 20013_CR16 K Nah (20013_CR77) 2017; 14 20013_CR50 CC Onyedum (20013_CR41) 2013; 107 MD Pham (20013_CR14) 2017; 14 ONO Nwankwo (20013_CR78) 2022; 17 D Etoori (20013_CR51) 2018; 21 H Sunpath (20013_CR24) 2021; 111 M Herce (20013_CR29) 2020; 7 20013_CR64 K Sikombe (20013_CR81) 2019; 14 20013_CR65 20013_CR22 20013_CR66 20013_CR67 20013_CR68 20013_CR69 C Chang (20013_CR42) 2023; 76 P Ondoa (20013_CR8) 2020; 36 HIV drug resistance report 2021 (20013_CR84) 2021 20013_CR60 20013_CR61 20013_CR62 20013_CR63 J Euvrard (20013_CR19) 2019; 109 R Warrier (20013_CR20) 2019; 22 LE Hermans (20013_CR27) 2020; 17 TR Glass (20013_CR11) 2019; 14 20013_CR17 20013_CR18 R Opito (20013_CR37) 2020; 15 20013_CR31 20013_CR75 20013_CR32 J Ndagijimana Ntwali (20013_CR36) 2019; 19 20013_CR76 20013_CR33 S Wilhelmson (20013_CR9) 2016; 9 H Sunpath (20013_CR26) 2018; 8 20013_CR79 S Swannet (20013_CR49) 2017; 9 MD Pham (20013_CR5) 2022; 22 B Nyagadza (20013_CR21) 2020; 9 20013_CR70 20013_CR71 20013_CR72 20013_CR73 20013_CR30 20013_CR74 AB Teshale (20013_CR87) 2021; 16 20013_CR28 SL Lecher (20013_CR7) 2021; 70 G Awungafac (20013_CR48) 2018; 13 G Namale (20013_CR39) 2019; 95 20013_CR3 20013_CR86 20013_CR2 20013_CR43 20013_CR4 20013_CR45 20013_CR6 T Apollo (20013_CR44) 2021; 16 20013_CR47 20013_CR80 ND Labhardt (20013_CR46) 2017; 20 R Nakalega (20013_CR38) 2020; 20 20013_CR83 20013_CR1 20013_CR40 20013_CR85 SE Rutstein (20013_CR34) 2015; 10 UL Abbas (20013_CR15) 2019; 14 O Keiser (20013_CR23) 2011; 25 R Moudachirou (20013_CR52) 2020; 10 C Iwuji (20013_CR25) 2020; 21 G Musengimana (20013_CR35) 2022; 22 |
| References_xml | – ident: 20013_CR76 – ident: 20013_CR17 doi: 10.1136/bmj.n71 – volume: 13 start-page: e0198686 issue: 6 year: 2018 ident: 20013_CR48 publication-title: PLoS ONE doi: 10.1371/journal.pone.0198686 contributor: fullname: G Awungafac – ident: 20013_CR53 – volume: 20 start-page: 21803 issue: 1 year: 2017 ident: 20013_CR46 publication-title: J Int AIDS Soc doi: 10.7448/IAS.20.1.21803 contributor: fullname: ND Labhardt – ident: 20013_CR57 – ident: 20013_CR72 – ident: 20013_CR80 doi: 10.1128/CMR.00097-18 – ident: 20013_CR6 – ident: 20013_CR18 – volume: 7 start-page: e807 issue: 12 year: 2020 ident: 20013_CR29 publication-title: Lancet HIV doi: 10.1016/S2352-3018(20)30188-0 contributor: fullname: M Herce – ident: 20013_CR2 – volume: 22 start-page: 1203 issue: 1 year: 2022 ident: 20013_CR5 publication-title: BMC Public Health doi: 10.1186/s12889-022-13504-2 contributor: fullname: MD Pham – ident: 20013_CR62 – volume: 8 start-page: 225 issue: 4 year: 2018 ident: 20013_CR26 publication-title: Public Health Action doi: 10.5588/pha.18.0063 contributor: fullname: H Sunpath – ident: 20013_CR66 – ident: 20013_CR22 doi: 10.1002/jia2.25476 – volume: 10 start-page: e0124748 issue: 4 year: 2015 ident: 20013_CR34 publication-title: PLoS ONE doi: 10.1371/journal.pone.0124748 contributor: fullname: SE Rutstein – volume: 16 start-page: e0253164 issue: 6 year: 2021 ident: 20013_CR87 publication-title: PLoS ONE doi: 10.1371/journal.pone.0253164 contributor: fullname: AB Teshale – ident: 20013_CR43 doi: 10.1371/journal.pone.0304487 – volume: 111 start-page: 299 issue: 4 year: 2021 ident: 20013_CR24 publication-title: South Afr Med J doi: 10.7196/SAMJ.2021.v111i4.15432 contributor: fullname: H Sunpath – volume: 70 start-page: 775 issue: 21 year: 2021 ident: 20013_CR7 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7021a2 contributor: fullname: SL Lecher – ident: 20013_CR73 – volume: 14 start-page: e0220337 issue: 8 year: 2019 ident: 20013_CR11 publication-title: PLoS ONE doi: 10.1371/journal.pone.0220337 contributor: fullname: TR Glass – ident: 20013_CR10 – volume: 14 start-page: 3 issue: 1 year: 2017 ident: 20013_CR14 publication-title: AIDS Res Ther doi: 10.1186/s12981-017-0131-5 contributor: fullname: MD Pham – ident: 20013_CR56 – volume: 22 start-page: 71 year: 2019 ident: 20013_CR20 publication-title: J Int AIDS Soc contributor: fullname: R Warrier – ident: 20013_CR33 doi: 10.1002/jia2.25543 – volume: 36 start-page: 918 issue: 11 year: 2020 ident: 20013_CR8 publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2020.0049 contributor: fullname: P Ondoa – volume: 20 start-page: 727 issue: 1 year: 2020 ident: 20013_CR38 publication-title: BMC Infect Dis doi: 10.1186/s12879-020-05461-1 contributor: fullname: R Nakalega – volume: 10 start-page: 33 issue: 1 year: 2020 ident: 20013_CR52 publication-title: Public Health Action doi: 10.5588/pha.19.0067 contributor: fullname: R Moudachirou – ident: 20013_CR63 – volume: 14 start-page: e0223573 issue: 10 year: 2019 ident: 20013_CR81 publication-title: PLoS ONE doi: 10.1371/journal.pone.0223573 contributor: fullname: K Sikombe – ident: 20013_CR45 doi: 10.1371/journal.pone.0225476 – ident: 20013_CR67 – volume: 169 start-page: 66 year: 2016 ident: 20013_CR82 publication-title: Soc Sci Med doi: 10.1016/j.socscimed.2016.09.027 contributor: fullname: M Remme – volume: 14 start-page: 16 issue: 1 year: 2017 ident: 20013_CR77 publication-title: Theor Biol Med Model doi: 10.1186/s12976-017-0062-9 contributor: fullname: K Nah – volume: 109 start-page: 174 issue: 3 year: 2019 ident: 20013_CR19 publication-title: South Afr Med J doi: 10.7196/SAMJ.2019.v109i3.13456 contributor: fullname: J Euvrard – volume: 21 start-page: 457 issue: 7 year: 2020 ident: 20013_CR25 publication-title: HIV Med doi: 10.1111/hiv.12877 contributor: fullname: C Iwuji – volume: 107 start-page: 608 issue: 10 year: 2013 ident: 20013_CR41 publication-title: Trans R Soc Trop Med Hyg doi: 10.1093/trstmh/trt071 contributor: fullname: CC Onyedum – ident: 20013_CR13 doi: 10.11604/pamj.2020.36.37.19046 – ident: 20013_CR74 – ident: 20013_CR3 doi: 10.1002/jia2.26005 – ident: 20013_CR32 doi: 10.4102/sajhivmed.v21i1.1085 – ident: 20013_CR4 – ident: 20013_CR70 – volume: 17 start-page: e1003037 issue: 2 year: 2020 ident: 20013_CR27 publication-title: PLoS Med doi: 10.1371/journal.pmed.1003037 contributor: fullname: LE Hermans – ident: 20013_CR55 – volume: 17 start-page: e0266159 issue: 3 year: 2022 ident: 20013_CR78 publication-title: PLoS ONE doi: 10.1371/journal.pone.0266159 contributor: fullname: ONO Nwankwo – ident: 20013_CR47 doi: 10.1002/jia2.25387 – ident: 20013_CR16 – ident: 20013_CR40 doi: 10.1016/S2352-3018(23)00118-2 – volume-title: Licence: CC BY-NC-SA 3.0 IGO year: 2021 ident: 20013_CR84 contributor: fullname: HIV drug resistance report 2021 – ident: 20013_CR64 – ident: 20013_CR85 doi: 10.1097/QAD.0000000000001964 – volume: 9 start-page: 206 issue: 4 year: 2017 ident: 20013_CR49 publication-title: Int Health doi: 10.1093/inthealth/ihx021 contributor: fullname: S Swannet – ident: 20013_CR59 – volume: 95 start-page: 405 year: 2019 ident: 20013_CR39 publication-title: Sex Transm Infect doi: 10.1136/sextrans-2018-053854 contributor: fullname: G Namale – ident: 20013_CR68 – volume: 16 start-page: e0245720 issue: 1 year: 2021 ident: 20013_CR44 publication-title: PLoS ONE doi: 10.1371/journal.pone.0245720 contributor: fullname: T Apollo – ident: 20013_CR83 – volume: 19 start-page: 8 issue: 1 year: 2019 ident: 20013_CR36 publication-title: BMC Infect Dis doi: 10.1186/s12879-018-3639-y contributor: fullname: J Ndagijimana Ntwali – volume: 21 start-page: e25194 issue: 10 year: 2018 ident: 20013_CR51 publication-title: J Int AIDS Soc doi: 10.1002/jia2.25194 contributor: fullname: D Etoori – ident: 20013_CR60 – volume: 15 start-page: e0239087 issue: 9 year: 2020 ident: 20013_CR37 publication-title: PLoS ONE doi: 10.1371/journal.pone.0239087 contributor: fullname: R Opito – volume: 22 start-page: 706 issue: 1 year: 2022 ident: 20013_CR35 publication-title: BMC Infect Dis doi: 10.1186/s12879-022-07692-w contributor: fullname: G Musengimana – ident: 20013_CR28 doi: 10.1111/hiv.13126 – ident: 20013_CR75 – volume: 76 start-page: e681 issue: 3 year: 2023 ident: 20013_CR42 publication-title: Clin Infect Dis doi: 10.1093/cid/ciac605 contributor: fullname: C Chang – ident: 20013_CR54 – volume: 25 start-page: 1761 issue: 14 year: 2011 ident: 20013_CR23 publication-title: AIDS doi: 10.1097/QAD.0b013e328349822f contributor: fullname: O Keiser – volume: 9 start-page: 177 issue: 4 year: 2020 ident: 20013_CR21 publication-title: Public Health Action doi: 10.5588/pha.19.0024 contributor: fullname: B Nyagadza – ident: 20013_CR79 – ident: 20013_CR31 doi: 10.7448/IAS.20.5.21649 – ident: 20013_CR58 – volume: 14 start-page: e0218649 issue: 7 year: 2019 ident: 20013_CR15 publication-title: PLoS ONE doi: 10.1371/journal.pone.0218649 contributor: fullname: UL Abbas – ident: 20013_CR71 – ident: 20013_CR1 – ident: 20013_CR12 – volume: 9 start-page: 29943 issue: 1 year: 2016 ident: 20013_CR9 publication-title: Glob Health Action doi: 10.3402/gha.v9.29943 contributor: fullname: S Wilhelmson – ident: 20013_CR50 – ident: 20013_CR65 – ident: 20013_CR86 – ident: 20013_CR69 – ident: 20013_CR30 doi: 10.1089/apc.2019.0055 – ident: 20013_CR61 |
| SSID | ssj0017852 |
| Score | 2.469943 |
| SecondaryResourceType | review_article |
| Snippet | The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving... Background The United Nations' 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and... BackgroundThe United Nations’ 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95%... Abstract Background The United Nations’ 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on... |
| SourceID | doaj proquest gale crossref pubmed |
| SourceType | Open Website Aggregation Database Index Database |
| StartPage | 2603 |
| SubjectTerms | Acquired immune deficiency syndrome Africa South of the Sahara - epidemiology AIDS Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral therapy Care and treatment Decentralisation Diagnosis Drug resistance Failure cascade Global health Health risks HIV HIV infection HIV Infections - drug therapy Human immunodeficiency virus Humans Literature reviews Measurement Monitoring Morbidity Mortality Nations Patient outcomes Public health Sub-Saharan Africa Systematic review Viral Load Viral load monitoring Viremia |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA-lJ6GI2qqrtUQoeJChmSSzk-etLS1bob1opbeQTxTa2dLZhf75vjeZXV09ePE6SSB5H8nvTd77hbFDnzLiYqUrB95V2qGnQwy5apXz0YCMYKjA-fJqOrvWn2-am9-e-qKcsEIPXAR3lKDxkGsZokdwoTVoPOLr2iGOF8LFUuYr5CqYGu8PWtPIVYmMmR71uAtTapDUZBW1qh43jqGBrf_vPfkPpDmcOOfP2NMRKvLjMsXnbCt1L9hO-c_GS_nQLvuOeuaUqHvLb-cu8rvBR-lnHQ-up-R3_qPjs4tvfJ1SzsecrLvUU1u_9NUXR7zNHS-vBn3ijv9ieOalumWPXZ-ffT2dVePrCVVAELKolFcY6onsMigISabsnDYQ2pRCzhkDMRl0qmsVwTU6CJ2TCQLhiA8i4GD1km138y69ZhxkwkDWQTLgdQPaR2-0jGra1kGCEBP2cSVMe19IMuwQXJipLaK3KHo7iN4-TtgJyXvdkwiuhw-odjuq3f5L7RP2gbRlyQ0XDy64sZoAJ0yEVvbYYJxJdIY4uf2Nnug-YbN5pW87um9viYKoJmpFmLD362YaSSlpXZovhz4CELAZ7POq2Ml6SQqUosD1zf9Y6lv2RJLl0lVYu8-2Fw_L9A6R0MIfDEb_EynJAjc priority: 102 providerName: Directory of Open Access Journals |
| Title | The viral load monitoring cascade in HIV treatment programmes in sub-Saharan Africa: a systematic review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39334013 https://www.proquest.com/docview/3115127929 https://www.proquest.com/docview/3110906689 https://doaj.org/article/e95b9f12cdb540449451411a11400ad8 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZNcimUkL43TRcVCj0UE9uSbSmXkA3ZbgsNJW3K0ovQsy0kdrrehfz8zMheh22hFx8s2cijGfmb0cwnQt4aHwAXM55oaXTCNVi6dDYkFdPGCZk7KbDA-fN5Obvkn-bFvA-4tX1a5XpNjAu1ayzGyA-RFSZDtjt5fPMnwVOjcHe1P0Jji-xAW4kpfWL6YdhFqESRrwtlRHnYwlqMCUI5R93IWHK78TOKnP3_rsx_4c3435nukd0eMNKTboYfkwe-fkIeddE22hURPSW_YLYppute0atGO3odLRVDdtTqFlPg6e-azj5-p0NiOe0zs659i23tyiRfNbI317Q7O-iIanrP80y7Gpdn5HJ69u10lvRnKCQWoMgyYYaBw5cGHSST1uc-aM2FtJX3NoQA7lhuuc8y5qQuuE158MKmAEqMTS08zJ6T7bqp_UtCZe7BndXSC2l4IblxRvDcsbLKbC7TdETer4WpbjqqDBVdDFGqTvQKRK-i6NXtiExQ3kNPpLmON5rFT9VbjfKyMDLAEJ0BZMm55IDvskyDE5em2okReYezpdAYlwttdV9TAANGWit1IsDbRFJDGNzBRk8wIrvZvJ5v1Rtxq-5VbkTeDM34JCam1b5ZxT6pBNgmoM-LTk-GT2KSMXRf9___8lfkYY46iVtd1QHZXi5W_jUgnaUZk61qXsFVnGbjqNpjsjM5O_9yMY6xA7heTH7cAVVzADo |
| link.rule.ids | 314,780,784,864,2102,12056,12223,12765,21388,27924,27925,31719,31720,33266,33267,33373,33374,33744,33745,43310,43579,43600,43805 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegewAJIb4pDDASEg8oWhI7jY8XtKFNHWwVgg3tzfInIG3paFppfz53iZupIPEa25FzvnN-d777mbE3NkTExUJmBqzJpEFLB-9iVgtjvYLSg6IC5-PZZHoqP51VZyng1qa0yvWe2G3Ufu4oRr5DrDAFsd3Bh8vfGd0aRaer6QqNm2yLmNOrEdva2599-TqcI9SqKtelMmqy0-JuTClCpSTtKER2tfE76lj7_92b_0Kc3Z_n4B67myAj3-3X-D67EZoH7E4fb-N9GdFD9hPXm1PC7jk_nxvPLzpbpaAdd6alJHj-q-HTw-98SC3nKTfrIrTU1q5s9s0Qf3PD-9uD3nPDr5meeV_l8oidHuyffJxm6RaFzCEYWWbCCnT58mgiCHChDNEYqcDVIbgYIzpkpZOhKIQHU0mXyxiUyxGWWJc7HCwes1Ezb8JTxqEM6NAaCAqsrEBab5UsvZjUhSshz8fs3VqY-rIny9Cdk6Emuhe9RtHrTvT6asz2SN5DTyK67h7MFz90shsdoLIQcYreIraUEiQivKIw6MblufFqzN7Samkyx-XCOJOqCnDCRGyldxX6m0RriJPb3uiJZuQ2m9frrZMZt_pa6cbs9dBMIyk1rQnzVdcnBwRuCvs86fVk-CQBQpAD--z_L3_Fbk1Pjo_00eHs83N2uyT9pIOvepuNlotVeIG4Z2lfJuX-A9e2_yo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+viral+load+monitoring+cascade+in+HIV+treatment+programmes+in+sub-Saharan+Africa%3A+a+systematic+review&rft.jtitle=BMC+public+health&rft.au=Kippen%2C+Annalise&rft.au=Nzimande%2C+Londiwe&rft.au=Gareta%2C+Dickman&rft.au=Iwuji%2C+Collins&rft.date=2024-09-27&rft.issn=1471-2458&rft.eissn=1471-2458&rft.volume=24&rft.issue=1&rft.spage=2603&rft_id=info:doi/10.1186%2Fs12889-024-20013-x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |